ATA Annual Meeting Program/Schedule at a Glance

The ATA Annual Meeting Program Committee is actively planning the Plenaries, Symposia and Meet the Professor/Scientist Sessions.  The preliminary schedule is listed below and is subject to change.

Basic Science Track

This year’s program has a dedicated programming track for basic scientists. Click here to learn more.

Wednesday, September 27, 2023

1:00 PM – 5:45 PM

Registration Open

7:00 AM – 4:30 PM

View Agenda

Endocrine Neck Advanced Ultrasound Course (REACHED REGISTRATION CAPACITY)

9:00 AM – 5:00 PM

View Agenda

Ridgway Trainees’ Conference (Included with Trainee registration for annual meeting.  Additional fee for other registration categories.)

7:30 AM – 3:00 PM

View Agenda

Leadership Development Workshop (additional registration fee)

8:45 AM  -4:00 PM

View Agenda

Interventional Endocrinology Workshop (additional registration fee)

3:30 PM – 5:30 PM

ATA Committee Meetings

After 5:30 PM


Thursday, September 28, 2023

7:00 AM – 5:45 PM

Registration Open

7:30 AM – 8:00 AM

Opening Remarks & Presidential Address

  • Julie Ann Sosa, MD, ATA President
  • Jacqueline Jonklaas, MD, PhD, Secretary
  • Amanda Perl, ATA Executive Director
  • Alexandra M. Dumitrescu, MD, PhD, Program Committee Co-Chair
  • Elizabeth Gardner Grubbs, MD, Program Committee Co-Chair

8:00 AM – 9:00 AM

Plenary – Year in Thyroidology

  • Graham Williams, MD, PhD – Basic Science Year in Review
  • Whitney Goldner, MD – Clinical Year in Review
  • Catherine Sinclair, MD – Surgical Year in Review

9:00 AM – 10:00 AM

Highlighted Oral Abstracts

Co-Chairs: Meredith Hartley, PhD and Whitney Goldner, MD

  • Kharisa Rachmasari, MD – “The Use of Medical Therapy for Thyroid Eye Disease in the Era of Teprotumumab”
  • Cheng Han, PhD – “Assessment of iodine status in U.S. women of reproductive age and pregnant women: NHANES 2001-2020”
  • Vera Tiedje, MD, PhD – “Tet2-mutant Clonal Hematopoiesis Drives Resistance to MAPK Inhibitors in BRAFV600E-mutant Anaplastic Thyroid Cancer”
  • Elizabeth Cahoon, PhD – “Risk of thyroid nodules in residents of Ukraine exposed as children or adolescents to iodine-131 from the Chornobyl accident”

10:00 AM – 6:15 PM

Exhibit Hall Open

10:00 AM – 10:30 AM

Poster Review and Break

10:35 AM – 11:35 AM

Symposia (4 concurrent)

  • Thyroid Subclinical Disease and Cardiovascular Risk
    • Co-Chair: Paul Ladenson, MD
    • Co-Chair: Layal Chaker, MD
    • Gabriela Brenta, MD – Metabolic Mechanisms in Subclinical Hypothyroidism
    • Anne Cappola, MD – Modifiers of CV risk in subclinical hypothyroidism
    • Donald McLeod, PhD – The association of subclinical hyperthyroidism with CVD
  • Understand Current Evidence for Redifferentiation Therapy
    • Co-Chair: Aime Franco, PhD
    • Co-Chair: Jim Fagin, MD
    • Christopher McCabe, PhD – The history of redifferentiation therapies in treatment of thyroid cancers
    • Alan L. Ho, MD, PhD – Clinical applications of redifferentiation therapies in treatment of RAI refractory thyroid cancers
    • Naifa Lamki Busaidy, MD – Molecular mechanisms of resistance of thyroid cancer redifferentiation therapies
  • Social Media for the Social Thyroidologist
    • Co-Chair: Xiaoyin Jiang, MD
    • Co-Chair: Arti Bhan, MD
    • Melissa Young, MD
    • Malini Gupta, MD
    • Michael Yeh, MD
    • Richard Ricciardi, PhD
  • Deiodinases in Developmental Transitions and Thyroid Disorders
    • Co-Chair: Antonio Bianco, MD, PhD
    • Co-Chair: Silvania da Silva Teixeira, PhD
    • Arturo Hernandez, MD – Deiodinases and brain development
    • Tatiana Fonseca, PhD – D2 effect in the liver and epigenetic effect of T3
    • Cristina Luongo, PhD – The role of the deiodinases in fibroadipogenic progenitors and muscle cells

11:35 AM – 12:45 PM

Poster Review and Lunch on Your Own

11:45 AM – 12:45 PM

12:55 PM – 1:45 PM

Ingbar & Braverman Award Lectures

  • Yaron Tomer, MD – Sidney H. Ingbar Distinguished Lectureship Award, “The Role of Autophagy in Autoimmune Thyroiditis: A New Paradigm”
  • Rosalind Brown, MD – Lewis E. Braverman Distinguished Lectureship Award, “Thyroid Disease in Children: A Fifty Year Perspective”

1:50 PM – 2:50 PM

Oral Abstracts

#1: Thyroid Cancer

Co-Chairs: Sana Ghaznavi and Sarimar Agosto Salgado    

  • Sarah Hamidi “Checkpoint Inhibition In Addition To DABRAFENIB + TRAMETINIB (DT) FOR BRAFV600E Mutated Anaplastic Thyroid Carcinoma (BRAFm-ATC)” (Oral 5)
  • Myriem Boufraqech “The identification of novel genetic vulnerabilities in anaplastic thyroid cancer cells to overcome resistance to BRAFV600E inhibitor using a genome-wide CRISPR screen” (Oral 6)
  • David Toro-Tobon “Efficacy and predictors of response to radioactive iodine redifferentiation therapy in previously iodine refractory papillary thyroid carcinomas” (Oral 7)
  • Martin Read “Rational Drug Design of VCP Inhibitors to Enhance NIS Function in Radioiodide Therapy”(Oral 8)

#2: Thyroid Hormone Action and Regulation

Co-Chairs: Alex Dumitrescu and Anthony Hollenberg

  • Randy Stout A New Transgenic Mouse Line To Allow Testing The Relationships Between Thyroid Hormone, Mitochondrial Morphology, And Gap Junction Connectivity With Subcellular Precision” (Oral 10)
  • Yuta Tanizaki Liver Development During Xenopus Tropicalis Metamorphosis Is Controlled By T3-Activation Of WNT Signaling” (Oral 9)
  • Ulrich Schweizer Identification Of Human TRIAC Transmembrane Transporters” (Late Breaking Oral 37)
  • Caroline Frädrich Identification And Characterization Of Novel DIO2 Inhibitors By High-Throughput-Screening Of Small Molecule Libraries” (Late Breaking Oral 38)

#3: Effects and Treatment of Autoimmune Thyroid Disease

Co-Chairs Mizuho Mimoto and Cary Mariash

  • Kimberly Cockerham “In Vitro Pharmacology and Phase 1/2 Results of VRDN-001, a Full Antagonist Antibody to IGF-1 Receptor in Thyroid Eye Disease (TED)” (Oral 11)
  • Carol Chiung-Hui Peng “Major cardiovascular outcomes of hyperthyroidism treated with antithyroid drug, radioactive iodine, or thyroidectomy: A Taiwanese national cohort” (Oral 12)
  • Paola Mina-Osorio “Incidence of Thyroid Eye Disease in the United States: Analysis of a Healthcare Claims Database” (Oral 13)
  • Julia Baran “Triiodothyronine Levels in Athyreotic Pediatric Patients During Levothyroxine Therapy: Is Monotherapy Adequate to Normalize Thyroid Hormone Levels?” (Late Breaking Oral 39)

3:00 PM – 4:00 PM

Exhibitor Networking Break

Diversity, Equity and Inclusion Networking Session

E. Chester Ridgway Trainee Conference: Basics of Thyroid Ultrasound (Trainees Only)

4:10 PM – 5:10 PM

Sawin Lecture – Celebrating ATA’s Centennial

  • David S. Cooper, MD, Introduction
  • Peter A. Kopp, MD, “The American Thyroid Association 1923 – 2023, Honoring our Past – Embracing our Future”

5:15 PM – 6:15 PM

Bobbi Smith Networking Social Hour – Celebrating ATA’s Centennial



Friday, September 29, 2023

7:00 AM – 5:00 PM

Registration Open

7:00 AM – 7:45 AM

Thyroid & Pregnancy Guidelines Update

  • Erik Alexander, MD, Co-Chair
  • Carol Chiung-Hui, MD, Co-Chair
  • Angela M. Leung, MD
  • Tim Korevaar, MD, PhD

7:50 AM – 8:00 AM

Recognition of Stanbury Medal, Distinguished Service, and Women in Thyroidology Woman of the Year Awardees and Morning Announcements from Co-Chairs

  • Carole Spencer, MD, PhD – John B. Stanbury Thyroid Pathophysiology Medal
  • M. Regina Castro, MD – Distinguished Service Award
  • Lisa Orloff, MD – Women in Thyroidology, Woman of the Year

8:00 AM – 9:00 AM

Plenary – Innovations in Research: Conversations for the Future

  • Julie Ann Sosa, MD, Professor and Chair of the UCSF Department of Surgery and Leon Goldman, MD, Distinguished Professorship in Surgery 
  • Anthony N. Hollenberg, MD,  John Wade Professor, Medicine & Chair of the Department of Medicine, Boston University Chobanian & Avedisian School of Medicine and Physician-in-Chief at Boston Medical Center
  • Leah Hubbard, Ph.D., Program Director- Brain and Head & Neck/Thyroid SPOREs, Translational Research Program (TRP), Chief Diversity Officer Division of Cancer Treatment and Diagnosis (DCTD) National Cancer Institute
  • Rebecca Schweppe, PhD, Professor of Medicine, Director, Cancer Biology Graduate Program and Research Director, Division of Endocrinology, Metabolism, and Diabetes, University of Colorado Anschutz School of Medicine
  • Sarah Temkin, MD, Associate Director for Clinical Research, NIH Office of Research on Women’s Health
  • Martha A. Zeiger, MD,  Director of the Center for Cancer Research Office of Surgeon-Scientist Career Development at the National Institutes of Health

9:00 AM – 9:50 AM

Van Meter & Galton Award Lectures

  • Anne Cappola, MD – Valerie Anne Galton Distinguished Lectureship Award, “Defining Thyroid Dysfunction: A Collaborative Approach”

9:50 AM – 4:00 PM

Exhibit Hall Open

9:50 AM – 10:20 AM

Poster Review and Break

10:20 AM – 11:20 AM

Symposia (4 concurrent)

  • Endocrine Disrupting Chemicals and the Thyroid: High Time to Act
    • Co-Chair: Heather Stapleton, PhD
    • Co-Chair: Leonidas Duntas, MD
    • Leonardo Trasande, MD, MPP – Endocrine disruptors and thyroid: human health and economic consequences, as well as needed policy actions
    • Nicole Deziel, PhD – Environmental exposures and thyroid cancer risk: new epidemiologic findings
    • Jennifer Sass, PhD – The endocrine disruptors screening program in the United States
  • Clinical Application of Updated ATA Guidelines and ACR-TIRADS: Value and Limitations of Sonographic Assessment of Thyroid Nodules
    • Co-chair: Jennifer Sipos, MD
    • Co-chair: Cord Sturgeon, MD
    • Susan Mandel, MD &  Jill Langer, MD – Evolution and Current State of ACR TIRADS and ATA Sonographic Pattern System
    • Merry Sebelik, MD – How to assimilate sonographic data, patient risk factors, and physical exam findings.
  • Quality of Life in Patients with Thyroid Disease
    • Co-Chair: Cari Kitahara, PhD
    • Co-Chair: Ulla Feldt-Rasmussen, MD
    • Ben James, MD – Patient-Reported Quality of Life Outcome Measures in the Thyroid Cancer Population
    • Archana Radhakrishnan, MD – The Role of primary care in thyroid cancer survivorship
    • Robin Peeters, MD – Quality of Life in Patients with Benign Disease
  • The use of Thyroid Analogues in the Treatment of Non-Thyroidal Disease
    • Co-Chair: Eveline Bruinstroop, MD
    • Co-Chair: Meredith Hartley, PhD
    • Soledad Bárez-López, PhD – Thyromimetic actions of Sobetirome and its Amide Prodrug Sob-AM2
    • Riccardo Zucchi, MD, PhD – Thyroid hormone analogues: an update
    • Josef Köhrle, PhD – How TH transmembrane transporters, deiodinases and T3 receptors contribute to action of T3 analogues

11:20 AM – 12:40 PM

Poster Review and Lunch on Your Own

11:30 AM – 12:15 PM

Meet the NIDDK Program Directors

11:30 AM – 12:30 PM

12:40 PM – 1:40 PM

Oral Abstracts

#4: Thyroid Cancer

Co-Chairs: Inigo Landa and Theodora Pappa

  • Sophie Leboulleux “ESTIMABL 2 trial: Thyroidectomy without Radioiodine in Patients with Low-Risk Thyroid Cancer: 5 years of follow-up” (Oral 14)
  • Lindsay Morton “Molecular Characteristics Distinguish Radiation-Induced Versus Sporadic Papillary Thyroid Carcinomas After the Chornobyl Nuclear Power Plant Accident” (Oral 15)
  • Viktoria Florentine Koehler “Taking Advantage of the Interleukin-6-Biology in Differentiated Thyroid Cancer to Stimulate Sodium Iodide Symporter (NIS)-Mediated Iodide Uptake in Engineered Mesenchymal Stem Cells” (Oral 16)
  • Linwah  Yip “A Prospective, Multicenter Study of Molecular-Based Initial Thyroidectomy for Bethesda V/VI Cytology” (Oral 17)

#5: Surgery

Co-Chairs: Anastasios Maniakas and R. Michael Tuttle

  • Anna Sawka “Decision Regret after Choosing Surgery or Active Surveillance for Management of Small, Low Risk Papillary Thyroid Cancer: Results of a Prospective Cohort Study” (Oral 18)
  • Helena Levyn “Surgical and Oncologic Outcomes after Conversion Surgery for Patients with Low-Risk Papillary Thyroid Carcinoma Initially Followed with Active Surveillance” (Oral 19)
  • Ian Hay “Can Ultrasound-Guided Ethanol Ablation Achieve Durable Long-Term Control of Recurrent Neck Nodal Metastases” (Oral 20)
  • Michelle Lundholm “The Safety and Adequacy of Performing Ultrasound-guided Thyroid Nodule FNA Biopsy while on Anticoagulant and Antiplatelet Medications” (Late-Breaking Oral 40)

#6: Thyroid Hormone Action and Regulation

Co-Chairs: Zeina Hannoush and Randy Stout

  • Xiaohan Zhang “Perturbation of Endoplasmic Reticulum Proteostasis Triggers Tissue Injury in the Thyroid Gland” (Oral 21)
  • David Sharlin “Cochlear Development and Auditory Function in a Mouse Model of Allen-Herndon-Dudley Syndrome” (Oral 22)
  • Liezhen Fu “Disruption of T3-Induced Epigenetic Regulator Mbd3 Leads To Growth Inhibition And Development Retardation In Xenopus” (Oral 23)
  • Julia Maier “Into the Unknown: The Actions of Thyroid Hormone in the Zona Incerta” (Oral 24)

1:50 PM – 2:50 PM

Symposia (4 Concurrent)

  • How can Neonatal Screening Keep up with Genetic Defects?
    • Co-Chair: Ari Wassner, MD
    • Co-Chair: Anita Boelen, PhD
    • Samuel Refetoff, MD- Measurement of rT3 and rT3/T3 in dried blood spot samples at birth
    • Paul van Trotsenburg, MD, PhD – Various neonatal screening approaches for CH
    • Athanasia Stoupa, MD – Genetics of congenital hypothyroidism: Modern concepts
  • Thyroid Hormone Mood and Cognition
    • Co-Chair: Jacqueline Jonklaas, MD, PhD
    • Co-Chair: Vishnu Sundaresh, MD
    • Mark Frye, MD – The association between TH and mood disorders
    • Jennifer Kruse, MD – T3 and depression
    • Matt Ettelson, MD – Treatment of Hypothyroidism and the use of T3:is this beneficial for mood disorders?
  • AI Chatbots – Ethical & Practical Implications
    • JP Brito, MD – Background & Introductions
    • David Toro-Tobon, MD – Examples of present and future uses of AI Chatbox in practice, research and scholarly activities
    • Derek O’Keeffe, MD – AI Chatbox pitfalls and ethical considerations
  • Managing Low Risk Thyroid Cancers – What’s the Right Answer in 2023?
    • Co-Chair: Laura Boucai, MD
    • Co-Chair: Leonardo Rangel, MD
    • Carmen Solorzano, MD
    • Timothy Huber, MD
    • Wendy Sacks, MD

2:50 PM – 5:15 PM

View Agenda

ATA Surgical Symposium – “Controversies in Thyroidology: Value and Challenges of Multidisciplinary Team Approach”

  • Panel 1 – “Case Discussions: Early Cancers and Nodules with Mutations”
    • Co-Chairs: Elizabeth Cottrill, MD and Peter Angelos, MD
      • Megan Haymart, MD
      • Susan Pitt, MD
      • Jonathon Russel, MD
      • Panel 2 – Case Discussions: Advanced Differentiated and Medullary Thyroid Cancer”
        • Co-Chairs: Lilah Morris-Weisman, MD and Mark Zafereo, MD
          • Erin Buczek, MD
          • Melanie Goldfarb, MD
          • Virginia Livolsi, MD
          • Mabel Ryder, MD

2:50 PM – 4:00 PM

Exhibitor Networking

3:00 PM – 4:00 PM

Expo Theater >

E. Chester Ridgway Trainee Conference: Bench to Bedside Case Presentations: Hypothyroidism Case and Hyperthyroidism Case (Trainees Only)


Special Interest Networking Sessions

  • Artificial Intelligence Networking Session
    • Co-Chair:  Juan P. Brito, MD
    • Co-Chair:  Nakkay Singh Ospina, MD
    • Co-Chair:  David Toro-Tobon, MD
  • Mouse models/Basic Science Meet Up
    • Co-Chair:  Megan Ritter, MD
    • Co-Chair:  Sheue-yann Cheng, PhD

4:05 PM – 4:50 PM

Discussion-Debates/MTP Workshops (4 concurrent)

  • Cancer Syndrome with Non-Medullary Thyroid Cancer
    • Co-Chair: Ana Hoff,
    • Co-Chair: Steven Waguespack, MD
    • Electron Kebebew, MD – Genetics, screening and management of inherited syndromes associated with non-medullary thyroid cancer
    • Huiying Wang, MD – Diagnostics of thyroid nodules and cancer in patients with familial syndromes
  • Impact of Drugs on Thyroid Physiology
    • Co-Chair: Julie Hallanger Johnson, MD
    • Co-Chair: Ramona Dadu, MD
    • Anupam Kotwal, MD – Win some, lose some: Cancer therapy and the thyroid
    • Daniele Cappellani, MD- Amiodarone and the Innocent Thyroid
  • Change in Treatment of Hyperthyroidism Over the Century
    • Co-Chair: Karen Tsai, MD
    • Co-Chair: Michael McDermott, MD
    • John C. Morris, MD – Endocrine history of treatment of hyperthyroidism & pioneers
    • Merry Sebelik, MD – Surgical history of treatment of hyperthyroidism
  • New omic Approaches in Understanding Thyroid Disease
    • Co-Chair: Jeffrey Knauf, PhD
    • Co-Chair: Myriem Boufraqech, PhD
    • Tom Giordano, MD, PhD – Integrated omics in in PTC and FTC
    • Erik S. Blomain MD, PhD – Omics in thyroid tumorigenesis and treatment response

5:00 PM – 6:00 PM

5:15 PM – 5:45 PM

ATA Annual Membership Meeting (Formerly Annual Business Meeting)



Saturday, September 30, 2023

7:00 AM – 5:00 PM

Registration Open

7:00 AM – 7:45 AM

Training Program Director Networking Session

7:45 AM – 7:50 AM

Morning Announcements from Co-Chairs

7:50 AM – 8:50 AM

Plenary – Diversity, Equity and Inclusion in Medicine & Academics: Reflections & A Call to Action

  • Panel Discussion
    • Carmelo Nucera, MD, PhD – Co-Chair
    • Sanziana Roman, MD – Co-Chair
    • Julie Ann Sosa, MD
    • Naifa Busaidy, MD
    • M. Regina Castro, MD
    • David Steward, MD
    • Joanna Miragaya, MD

8:50 AM – 9:50 AM

Women in Thyroidology Plenary

  • Marie A. Bernard, MD, Chief Officer for Scientific Workforce Diversity, National Institutes of Health

9:50 AM – 1:00 PM

Exhibit Hall Open

9:50 AM – 10:20 AM

Poster Review and Break

10:25 AM – 11:25 AM

Symposia (4 concurrent)

  • Research Grant Session
  • Thyroid and Aging, Treatment in Older Adults
    • Co-Chair: Thanh Hoang, MD
    • Co-Chair: Sina Jasim, MD
    • Jenna Mammen, MD – How thyroid function tests change with aging
    • Maria Papaleontiou, MD – Considerations in titrating treatment in older individuals
    • Giuseppe Barbesino, MD – Special considerations about Graves’ disease in older individuals
  • Treatment of ATA Intermediate Risk DTC
    • Co-Chair: Mara Roth, MD
    • Co-Chair: Dave Steward, MD
    • Cosimo Durante, MD – Post-Operative Management of Intermediate Risk DTC: Short Term and Long-term
    • Abbey Fingeret, MD – Surgical Decision Making in the Treatment of Intermediate RiskDTC 
  • The Roles of Autophagy and Thyroid Hormone in the Pathogenesis and Treatment of NAFLD
    • Chair: Gregory A. Brent, MD
    • Paul Yen, MD – Thyroid hormone regulation of autophagy and NAFLD
    • Joao Anselmo, MD – The risk of NAFLD in Resistance to Thyroid Hormone beta (RTHT beta)
    • Eva Wirth, PhD – Thyroid hormones as a disease modifier and therapeutic target in nonalcoholic steatohepatitis

11:25 AM – 12:40 PM

Poster Review and Lunch on Your Own

11:30 AM – 12:30 PM

Expo Theater >

Multicenter Clinical Trials Networking Session

12:40 PM – 1:40 PM

Plenary – Artificial Intelligence

  • Co-Chair: Trevor Angell, MD
  • Co-Chair: Johnson Thomas, MD
  • Nestoras Mathioudakis, MD, The Current State of AI and Future Applications of AI in Medicine and Beyond
  • Marco Alvarez, MD, Artificial Intelligence in Thyroid Nodule and Thyroid Cancer Imaging
  • Naykky Singh-Ospina, MD, Use of AI in Disorders of Thyroid Function: Graves’ Disease, Thyroid Eye Disease, Hashimoto, and Hypothyroidism

1:50 PM – 2:50 PM

Expo Theater >

Oral Abstracts

#7: Technology & Thyroid

Co-Chairs: Nikta Pozdeyev and David Toro Tobon

  • Eun Ju  Ha “AI-Thyroid: Pilot Results for Evaluating Thyroid Malignancy in Children” (Oral 25)
  • Andrew Thomas “Novel Integration of Topological Data Analysis Into a Multimodal Machine Learning Model to Predict Follicular Carcinoma on Ultrasound” (Oral 26)
  • Moon  Jae Hoon “Performance validation of a machine learning-assisted system for predicting clinical activity score in thyroid-associated orbitopathy and comparison with ophthalmologists” (Oral 27)
  • Daniel  Campbell “Evaluating ChatGPT Queries on Thyroid Nodules for Patient Education” (Oral 28)


#8 Thyroid Nodules and Goiter

Co-Chairs: Poorani Goundan and Mark Lupo

  • Ai Yoshihara “Long-term clinical outcomes after radioactive iodine treatment for an autonomous functional thyroid nodule” (Oral 29)
  • Maria  Mavromati “Unnecessary thyroid surgery rate in the absence of molecular testing”  (Oral 30)
  • Mason Stillman “Molecular Testing for Bethesda III Thyroid nodules: Trends in Implementation, Cytopathology Call Rates, Surgery Rates, and Malignancy Yield at a Single Institution” (Oral 31)
  • Melbin Thomas “False-Negative Biopsy Rates Are Not Increased for Thyroid Nodules >4 cm if Non-Surgical Management is Included in Analysis” (Oral 32)


#9: Quality of Life & Health Disparities

Co-Chairs: Carrie Cunningham and Stephanie Fish

  • Thomas Szabo Yamashita “Patient Reported Outcomes: What symptoms do long term thyroid cancer survivors experience?” (Oral 33)
  • Hattie  Huston-Paterson “Rural-urban Disparities in the Continuum of Thyroid Cancer Care: Analysis of 92,794 cases” (Oral 34)
  • Gerasimos Sykiotis “Predictors of Poor Emotional Quality of Life in Patients with Differentiated Thyroid Cancer – Results of a Prospective International Study. “(Oral 35)
  • Debbie Chen “Barriers to Getting in The Door for Thyroid Cancer Care” (Oral 36)

2:00 PM – 5:00 PM

View Agenda

ATA Pediatric Thyroid Symposium

  • Percutaneous Approaches to Neoplastic Thyroid Disease in Children:  Who and When?
    • Chair: Chelsey Baldwin, MD
    • Speaker: Jennifer Kuo, MD
  • Pediatric Abstract Highlights
    • Co-Chair: Larry Fox, MD
    • Co-Chair: Zoltan Antal, MD
    • Einas Alkhatib, MD – Pediatric Graves’ Disease: Improvement of Free T4 in Newly Diagnosed Patients Through a Multifaceted Quality Improvement Approach
    • Julia Baran – Incidental Papillary Thyroid Microcarcinomas in Pediatric Patients Following Definitive Treatment for Graves’ Disease
    • Alyssa Webster, MS – Recurrent or Persistent Thyroid Carcinoma in the Pediatric Population after Radioactive Iodine Treatment: A Systematic Review and Meta-Analysis
  • Pediatric Tumor Board
    • Co-Chair: Scott Manning, MD
    • Co-Chair: Christine Cherella, MD
    • Priya Vaidyanathan, MD
    • Jeff Rastatter, MD
  • Managing Children with Moderate Risk MEN2A
    • Chair: Jonathan Wasserman, MD
    • Speaker: Rosa Elisei, MD

3:00 PM – 3:50 PM

Highlighted Posters

#1: Thyroid Cancer & Surgery

Co-Chairs: Benjamin Gigliotti and Mimi Hu

  • Justyna Gleba “Targeting Aggressive Thyroid Cancers with TSHR CART Cells” (Highlighted Poster 100)
  • Debora Thomaz “Plasma-Based Genotyping For Monitoring Patients With Thyroid Cancer” (Highlighted Poster 101)
  • Highlighted Poster 102 – Withdrawn
  • Marin Kheng  “Reoperation Rates after Initial Thyroid Lobectomy for Patients with Thyroid Cancer: A National Cohort Study”  (Highlighted Poster 103)
  • Jennine Weller “Few Patients With Medullary Thyroid Cancer Undergo Genetic Testing or Counseling” (Highlighted Poster 104)
  • Ludovico Sehnem “Longitudinal Thyroid Ultrasound Screening in Patients with Familial Adenomatous Polyposis: Surveillance Recommendations” (Highlighted Poster 105)

#2: Thyroid Cancer, Pregnancy & Development, Health Disparities / Health Equity

Co-Chairs: Soffie Bliddal and Angela Leung

  • Alaina  Carr “Psychometric Evaluation of a New Instrument to Assess the Symptoms Following Radioactive Iodine Therapy among Patients with Differentiated Thyroid Cancer: SAlivary, LAcrimal, NaSal (SALANS) Questionnaire” (Highlighted Poster 106)
  • Christian Hernandez-Padilla “BRAF Alterations are Linked to Changes in Thyroid Cancer Motility and Contractility in Nanofibrous Substrates with Tunable Fiber Spacing and Durotactic Regions” (Highlighted Poster 107)
  • Enrique González-Madrid “Gestational hypothyroxinemia induces an acute inflammatory state at the maternal-fetal interface and produces an autistic-like phenotype in the offspring with more accentuation in males.” (Highlighted Poster 108)
  • Jordan Ross “Improving Management of Congenital Hypothyroidism through Quality Improvement Cycles”  (Highlighted Poster 109)
  • Judy Qiang “Association between serum Thyroid Stimulating Hormone (TSH) and Cancer Recurrence among Adult Patients with Differentiated Thyroid Cancer (DTC): A Retrospective Cohort Study” (Highlighted Poster 110)
  • Jiangnan Hu “Targeting Ferroptosis in BRAFV600E-Mutant Anaplastic Thyroid Cancer – A Novel Treatment Strategy” (Late Breaking Highlighted Poster 117)

#3: Disorders of Thyroid Function, TH Action, Metabolism and Regulation, Thyroid Imaging

Co-Chairs: Raquel Cano and Megan Ritter

  • Ziyu Zhu “Exploring the Effects of Thyroid Hormones on Oligodendrocyte Progenitor Cell Differentiation for Potential Therapeutic Use in Myelin Repair” (Highlighted Poster 111)
  • Highlighted Poster 112 – Withdrawn
  • Maryam Mansoori “THYROID AND THE BRAIN – TSH ENHANCES NEURITE OUTGROWTH” (Highlighted Poster 113)
  • Jaemin  Park “Cost-Effectiveness of a Digital Therapeutic for Managing Hyperthyroidism: Evaluation of GlandyTM” (Highlighted Poster 114)
  • Highlighted Poster 115 – Withdrawn
  • Highlighted Poster 116 – Withdrawn

4:05 PM – 4:50 PM

Discussion-Debates/MTP Workshops (3 concurrent)

  • Oncocytic Tumors – New Definition and How They Differ from Previous Classifications
    • Co-Chair: Kartik Viswanathan, MD, PhD
    • Co-Chair: Marina Nikiforova, MD
    • Esther Diana Rossi, MD – Updates on WHO classification and FNA diagnostics of oncocytic tumors
    • Ian Ganly, MD – Molecular genetics and therapeutic approaches to oncocytic tumors
  • Management of Patients with Thyroid Disorders Undergoing IVF
    • Chair: Tim Korevaar, MD, PhD
    • Kristien Boelaert, MD, PhD – Subclinical hypothyroidism and thyroid auto-antibodies in women with subfertility or recurrent pregnancy loss
    • Jennifer Eaton, MD – Thyroid hypofunction and autoimmunity in women undergoing assisted reproductive technology
  • Tumor vulnerability: rationale for combined therapy in BRAFV600E thyroid cancers
    • Co-Chair: Carmelo Nucera, MD, PhD
    • Co-Chair: Maria Cabanillas, MD
    • Rebecca Schweppe, PhD – Preclinical models to sensitize BRAFV600E pathway inhibitors and overcome resistance of thyroid cancer cells
    • Lori Wirth, MD – Precision thyroid oncology for patients: therapeutic implementations tackling refractoriness to BRAFV600E inhibitors and TKIs

5:00 PM – 8:00 PM


8:00 PM – 11:00 PM

ATA Centennial Celebration Party (Additional registration required)

  • Join us for an evening of dancing and karaoke as we celebrate the ATA’s Centennial.  Party refreshments and snacks will be served.

Sunday, October 1, 2023

8:00 AM – 11:00 AM

Registration Open

8:15 AM – 9:15 AM

Parallel Sessions

  • Tumor Board
    • Co-Chair: Tracy Wang, MD
    • Co-Chair: Lindsay Bischoff, MD
    • Marika Russell, MD
    • Bryan McIver, MD
    • Robert Flavell, MD
    • Peter Sadow, MD
  • Genetic Defects in Humans and Mice Affecting Thyroid Function
    • Co-Chair: Peter Arvan, MD, PhD
    • Nadia Schoenmakers, MD, PhD – Homozygosus loss-of-function mutations in SLC26A7 cause goitrous congenital hypothyroidism
    • Mingyao Liu, MD – Role of XB130 in normal thyroid function
    • Gerasimos Sykotis – The Keap1/Nrf2 signaling pathway in the thyroid

9:15 AM – 11:15 AM

Parallel Sessions

  • Arthur Bauman Symposium – Insights Into the New ATA Guidelines
    • Co-Chair: Ellen Marqusee, MD
    • Co-Chair: Spyridoula Maraka, MD
    • Thyroid Nodules: Lisa Orloff, MD & Susan Mandel, MD
    • Differentiated Thyroid Cancer: Julie Ann Sosa, MD & Matt Ringel, MD
    • Pediatric Thyroid Cancer: Jonathan Wasserman, MD, Andy Bauer MD, & Steven Waguespack, MD
  • Basic/Translational Symposium
    • Recent Progress on the Effect of Thyroid Hormone Signaling in Development in Animal Models
      • Co-Chair: Yun-Bo Shi, PhD
      • Co-Chair: Salma Khan, PhD
      • David Parichy, PhD – Thyroid hormone regulation of skin morphogenesis in zebrafish
      • Sheue-yann Cheng, PhD – TR mutant zebrafish
      • Douglas Forest, PhD – Thyroid hormone signaling in mouse visual/auditory development
    • Thyroid Hormone Transporters
      • Co-Chair: Edward Visser, MD
      • Co-Chair: Ulrich Schweizer, PhD
      • Stefan Groeneweg, MD, PhD – MCT8 deficiency: integrated genomic, functional, structural and predictive insights
      • Ana Guadano-Ferraz, PhD – A knockin mouse model for Mct8 deficiency.
      • Federico Salas-Lucia, PhD – New Roles for MCT8 on Brain Development and Function

11:15 AM